Attila Resources increases JORC resource at US coking coal project

Published 02-APR-2014 08:39 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

It’s busy times for Attila Resources (ASX: AYA) after it appointed a new top leadership team and increased the JORC resource at its coking coal mining project in Alabama, USA.

AYA has a 70% stake in The Kodiak Coking Coal Mining Project in Alabama with a maiden JORC resource of 48.2M tonnes, aiming to bring a 2Mtpa mine on stream by 2015.

New coking coal deposit in Alabama

But AYA’s exploration effort at Kodiak has just increased its JORC resource by fining an inferred deposit of coking coal rated at 48.3M tonnes, boosting the company’s global resource by 61% to over 126M tonnes.

Coking coal is a high quality form of coal mainly used during the steel smelting process. It currently sells for around $140 a tonne. The coking coal AYA will mine at Kodiak is highly rated due to its low ash and sulphur content.

AYA requires capex of $27M for a staged development with full production capex of $52.1M. Infrastructure such as a processing plant, washing facility and cargo loading areas are already in place, pushing capex down and putting it in the lowest 10% of metallurgical coal producers.

Evan Cranston, Executive Director of AYA, says the second JORC resource at Kodiak is a boon for AYA as it seeks support in bringing its project on stream. “The robust maiden resource at Seymour provides confidence in the potential for these assets to significantly expand Attila’s future production profile, with only a modest incremental capex given the close proximity to Attila’s existing infrastructure,” he says.

New leaders for AYA

With much larger coking coal resources now on hand, the company has appointed a new leadership team to guide the company’s effort in bringing The Kodiak Coking Coal Project into production by 2015. The former managing director of Grange Resources (ASX:GRR) Russell Clarke has already taken the helm as Non-Executive Chairman, bringing with him a wide range of experience in the US coal industry.

Meanwhile, former BHP Billiton and Peabody Energy manager Scott Sullivan has been appointed as AYA’s new Chief Executive. Scott visited the Kodiak Project recently and says he was encouraged by what he saw. “The Kodiak Project is well positioned to progress toward production with very modest hurdles relative to the majority of projects I have been involved with in the past,” he says, singling out Kodiak’s low capex as a major advantage. “The significant pre-exisiting infrastructure, well established logistics network and premium quality coking coal product place Attila in an incredibly strong position to progress The Kodiak Project towards commercial production in the near term.”



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X